Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berobenatide - Pfizer

Next Previous
Drug Profile

Berobenatide - Pfizer

Alternative Names: GLP-1 receptor agonist - Pfizer; MET-097; MET-097o; MET-097i; PF-08653944; PF’3944

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metsera
  • Developer Pfizer
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 31 Aug 2026 Pfizer plans a phase III VESPER-JW trial for Obesity in Japan (SC, Injection) in September 2026 (NCT07794761)
  • 31 Aug 2026 Pfizer plans a phase III VESPER-JM trial for Obesity in Japan (SC) (NCT07794774)
  • 28 Aug 2026 Pfizer plans a phase III trial for Obesity in China (Parenteral, Injection) in September 2026 (NCT07792954)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top